ATL-001 is a cell therapy commercialized by Achilles Therapeutics, with a leading Phase II program in Metastatic Melanoma. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of ATL-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ATL-001 is expected to reach an annual total of $44 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ATL-001 Overview

ATL-001 is under development for the treatment of advanced non-small cell lung cancer and metastatic or recurrent melanoma, head and neck squamous cell carcinoma. The therapeutic candidate comprises of clonal neoantigen T cells (cNeT) isolated from patients own tumor infiltrating lymphocytes (TILs). It is administered through intravenous route.

It was also under development for the treatment of renal cell carcinoma.

Achilles Therapeutics Overview

Achilles Therapeutics is a biopharmaceutical company focused on developing personalized T-cell therapies targeting neoantigens present on the surface of cancer cells. It’s lead indications for advanced non-small cell lung cancer and recurrent metastatic melanoma. Achilles uses its proprietary PELEUS bioinformatics platform to identify clonal neoantigens specific to that patient and enable the development of personalized cell therapies targeting cancer cells, without harming healthy tissues. It also operates in Stevenage, Hertfordshire, the UK. Achilles Therapeutics is headquartered in London, Greater London, UK.

The operating loss of the company was US$64.2 million in FY2021, compared to an operating loss of US$33.7 million in FY2020. The net loss of the company was US$61.1 million in FY2021, compared to a net loss of US$33.2 million in FY2020.

For a complete picture of ATL-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.